Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a fizzy fiber drink soothe the gut woes of Weight-Loss drugs?

NCT ID NCT07744360

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study tests whether drinking a prebiotic soda—a fizzy drink with added fiber—can ease the nausea, constipation, and other stomach issues that often come with GLP-1 weight-loss medications like semaglutide and tirzepatide. About 80 adults currently taking these drugs and experiencing gut side effects will be randomly assigned to drink the soda daily or stick with their usual fluids. Researchers will track changes in gastrointestinal symptoms, stool habits, quality of life, and diet to see if the soda offers relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prebiotic soda (6 g dietary fiber per 12 fl oz serving)
What this could lead to
If it works, this could offer a simple, drug-free way to manage common gut side effects of GLP-1 weight-loss medications, potentially improving comfort and quality of life for users.
What could go wrong
This is a small pilot study, so results may not apply broadly. The soda's fiber could also worsen symptoms in some people, and the open-label design means participants know what they're drinking, which can bias results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Feb 2026

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 - 65 years old * Currently on prescribed GLP-1 Agonist therapy (semaglutide and/or tirzepatide) for weight management for at least 1 week to 1 month AND experiencing at least one GI side effect (i.e., nausea, diarrhea, constipation, dyspepsia, abdominal pain) * Not taking any prescription medications for side effect management * Not taking fiber supplements to manage constipation * Confirmation of planning to be on GLP-1 therapy for at least 3 more months * Open to consuming a carbonated soda beverage * In good general health at the time of screening * Able to read and understand English * Able to read, understand, and provide informed consent * Able to use a personal smartphone device and download Chloe by People Science * Able to receive shipment of the product at an address within the United States (No PO boxes, APO military PO boxes, Hawaii or Alaska addresses) * Able to complete study assessments over the course of up to 13 weeks * No known diagnosis of IBS or IBD Exclusion Criteria: * Do not have a personal smartphone, internet access, or unwilling to download Chloe * Received any investigational therapies or treatments within 30 days prior to randomization. * Have gastrointestinal illnesses * Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder * Currently pregnant, planning to become pregnant in the next 4 months, or breastfeeding * Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes * Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes * Known hypersensitivity or previous allergic reaction to OLIPOP prebiotic soda or any prebiotic beverage * Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator * Current consumer of prebiotic sodas

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gi symptoms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • People Science

    Los Angeles, California, 90034, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.